BioSpace News Archive

Kala Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has accepted an investigational new drug application for the company’s lead product candidate, KPI-012, a human mesenchymal stem cell secretome, initially in development for the treatment of persistent corneal epithelial defect.

Everest Medicines, a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced that the first phase of its global manufacturing site dedicated to mRNA vaccine production in Jiashan, Zhejiang Province has initiated operation and successfully carried out trial production runs.